Tobramycin therapy of infections due to Pseudomonas aeruginosa in patients with cystic fibrosis: effect of dosage and concentration of antibiotic in sputum.

Established respiratory infections with mucoid Pseudomonas aeruginosa in patients suffering from cystic 
fibrosis were treated with conventional as well as larger doses of 
tobramycin. The infection was eradicated in four of the 17 patients 
treated, but the duration of follow-up study of one patient was 
short. It appeared that treatment was most successful in those patients 
in whom the highest peak concentrations of tobramycin in sputum were 
obtained. No side effects were noted, even when tobramycin was given 
in large doses for two weeks. 